Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

On Thursday, Immutep Limited (NASDAQ:IMMP) released data from the INSIGHT-003 Phase 1 trial of eftilagimod alpha (efti) in combination with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer (1L NSCLC) patients.

The survival data as of data cutoff of Oct. 15 from the triple combination therapy in patients irrespective of PD-L1 expression with a minimum followup of 22 months (N=21) shows:

• Median Overall Survival (OS) of 32.9 months.
• Median Progression-Free Survival (PFS) of 12.7 months.
• 24-month Overall Survival (OS) of 81.0%.

Also Read: Australia Based Cancer Focused Immutep’s Lead Cancer Drug Shows ‘Meaningful Response’ In Untreated Head & Neck Cancer, Stock Soars

The company ...

Full story available on Benzinga.com